Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug
Journal of Biotechnology and Biomedicine · 2026 · 09 (03)
DOI: 10.26502/jbb.2642-91280222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biotechnology and Biomedicine, 2026. Verfasst von Jih Ru Hwu und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hwu, J. R., Panja, A., Tsay, S. C., Huang, W., Pradhan, T. K., Yeh, C., Su, W. C., Yang, L. X., & Shieh, D. B. (2026). Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug. Journal of Biotechnology and Biomedicine, 09(03). https://doi.org/10.26502/jbb.2642-91280222
Vancouver
Hwu JR, Panja A, Tsay SC, Huang W, Pradhan TK, Yeh C, et al. Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug. Journal of Biotechnology and Biomedicine. 2026;09(03). doi:10.26502/jbb.2642-91280222
BibTeX
@article{Hwu2026,
author = {Hwu, Jih Ru and Panja, Avijit and Tsay, Shwu Chen and Huang, Wen-Chieh and Pradhan, Tapan Kumar and Yeh, Chen-Sheng and Su, Wu Chou and Yang, Li Xing and Shieh, Dar Bin},
title = {Synergism and Antagonism of Lenalidomide–(β-D-Ribofuranose 2',3'-phosphodiester)–Paclitaxel as a Selective Anticancer Codrug},
journal = {Journal of Biotechnology and Biomedicine},
year = {2026},
volume = {09},
number = {03},
doi = {10.26502/jbb.2642-91280222}
}
EUVIMED